Three peptides from the ANF prohormone NH(2)-terminus are natriuretic and/or kaliuretic

1990 ◽  
Vol 258 (5) ◽  
pp. F1401-F1408 ◽  
Author(s):  
D. R. Martin ◽  
J. B. Pevahouse ◽  
D. J. Trigg ◽  
D. L. Vesely ◽  
J. E. Buerkert
Keyword(s):  
Atrial Natriuretic Factor ◽  
Wistar Rats ◽  
Urine Volume ◽  
Fractional Excretion ◽  
Potassium Excretion ◽  
Terminal Portion ◽  
Urine Sodium ◽  
Fractional Excretion Of Sodium ◽  
Urinary Potassium ◽  
Sodium And Potassium

The present investigation was designed to determine whether peptides derived from the NH(2)-terminal portion of the 126-amino acid prohormone (pro) of atrial natriuretic factor (ANF) have natriuretic and diuretic properties similar to ANF. Three peptides consisting of amino acids 1-30 [(proANF-(1-30)], 31-67 [proANF-(31-67)], and 79-98 (proANF-(79-98)] of the ANF prohormone were tested and compared with the COOH-terminus peptide (ANF) with respect to their ability to increase urine volume, urine sodium and potassium excretion, and glomerular filtration rate (GFR) in anesthetized Munich-Wistar rats. Each of these peptides except proANF-(79-98) caused a significant diuresis (P less than 0.05) when infused at their respective 100 ng.kg body wt-1.min-1 concentrations for 120 min. ProANFs-(1-30), (31-67), (79-98), and (99-126) (ANF) increased sodium excretion by 231, 973, 167, and 1,405%, respectively. The fractional excretion of sodium compared with control was significant at P less than 0.05, P less than 0.01, and P less than 0.05 for proANFs (1-30), (31-67), and (99-126), respectively. ProANF-(79-98) did not significantly increase the fractional excretion of sodium, but it was the only peptide from the NH(2)-terminus of the prohormone that significantly increased the fractional excretion of potassium's ProANF-(31-67) did not increase urinary potassium excretion. ProANF-(1-30), (79-98), and ANF significantly (P less than 0.05) increased urinary potassium excretion. None of these peptides significantly enhanced GFR. In conclusion, three peptides from the NH(2)-terminus of the ANF prohormone as well as ANF (the COOH-terminus) have either natriuretic, kaliuretic, and/or diuretic properties, but the respective ability of each of these peptides to produce these effects varies considerably.

Dissociation of renal interstitial hydrostatic pressure and natriuresis of atrial natriuretic factor

1990 ◽  
Vol 258 (2) ◽  
pp. R481-R486
Author(s):  
A. A. Khraibi ◽  
D. M. Heublein ◽  
J. C. Burnett ◽  
F. G. Knox
Keyword(s):  
Hydrostatic Pressure ◽  
Atrial Natriuretic Factor ◽  
Wistar Rats ◽  
Fractional Excretion ◽  
Contralateral Kidney ◽  
Time Control ◽  
Natriuretic Factor ◽  
Fractional Excretion Of Sodium ◽  
Male Wistar Rats ◽  
Atrial Natriuretic

The objective of these experiments was to test the hypothesis that renal interstitial hydrostatic pressure (RIHP) plays an important role in the natriuretic effect of atrial natriuretic factor (ANF) in anesthetized Wistar rats. Three groups of male Wistar rats were used in this study. Two groups were infused with different doses of ANF, and the third group was a time control. In all groups, one kidney was acutely decapsulated, and the contralateral kidney was used as control. Renal decapsulation was used to control RIHP. In one group, 3 micrograms.kg-1.h-1 of synthetic ANF were infused intravenously (iv) and produced a plasma level of ANF (PANF) of 810 +/- 186.5 pg/ml. This pharmacological dose of ANF produced a significant increase in RIHP of the control kidney from 9.5 +/- 0.8 to 11.1 +/- 1.3 mmHg (P less than 0.05) but not in the decapsulated kidney [from 7.1 +/- 0.6 to 8.1 +/- 0.9 mmHg, not significant (NS)]. However, the changes in fractional excretion of sodium (FENa) and urine flow rate (V) as a result of ANF infusion were similar in both kidneys. In the decapsulated kidney, FENa and V increased by 1.53 +/- 0.41% and 26.21 +/- 5.98 microliters/min, respectively, from control to ANF infusion periods. In the control kidney, FENa and V increased by 1.60 +/- 0.28% and 31.61 +/- 5.87 microliters/min, respectively, from control to ANF infusion periods. In the second group, 1 microgram.kg-1.h-1 iv of synthetic ANF was infused and produced 165.2 +/- 29.3 pg/ml of PANF.(ABSTRACT TRUNCATED AT 250 WORDS)

Do vasopressin and oxytocin have synergistic renal effects in the conscious rat?

1995 ◽  
Vol 144 (3) ◽  
pp. 441-448 ◽  
Author(s):  
R J Windle ◽  
J M Judah ◽  
M L Forsling
Keyword(s):  
Filtration Rate ◽  
Fractional Excretion ◽  
Potassium Excretion ◽  
Conscious Rat ◽  
Renal Effects ◽  
Fractional Excretion Of Sodium ◽  
Dose Dependent ◽  
Higher Doses ◽  
Sodium And Potassium ◽  
Tubular Component

Abstract The renal effects of arginine vasopressin and oxytocin were studied in the conscious unrestrained rat infused with 0·077 m NaCl. Peptides were infused at rates of 24 and 160 pmol/min (vasopressin) or 30 and 200 pmol/min (oxytocin) either alone or as a combination of the two lower or two higher doses. The rates of infusion were selected to give ratios of oxytocin:vasopressin similar to those seen in the plasma of euhydrated and dehydrated rats. Vasopressin produced dose-dependent antidiuretic and natriuretic responses, the natriuresis commencing after 15–30 min infusion. Oxytocin produced dose-dependent diuretic and natriuretic responses, the natriuresis commencing within the first 15 min of infusion. Combined infusion of vasopressin and oxytocin produced dose-dependent antidiuretic responses which were comparable to those seen with vasopressin alone. The natriuretic response from combined infusion at the higher rate appeared to have the greater magnitude for individual 15-min periods of the vasopressin response combined with the longer duration of the oxytocin response. Although the total natriuretic response was therefore greater, this difference failed to reach significance. Only the higher rates of infusion of vasopressin and oxytocin significantly increased the clearance of sodium, by 53 ± 23 and 62 ± 18% and glomerular filtration rate (GFR) by 23 ± 4 and 23 ± 4% respectively. The clearance of sodium during the combined hormone infusion was significantly greater (109 ± 21%), while the rise in GFR at 23 ± 5% was comparable to that seen when each hormone was given separately. Both fractional excretion of sodium and potassium excretion were also significantly elevated by this combined infusion, suggesting an additional tubular component to the response. Although no synergistic effect of neurohypophysial hormones on the antidiuresis was found in the conscious rat, they may act together to promote sodium excretion Journal of Endocrinology (1995) 144, 441–448

Comparison of the effects of parathyroid hormone (PTH) and recombinant PTH-related protein on bicarbonate excretion by the isolated perfused rat kidney

1990 ◽  
Vol 126 (3) ◽  
pp. 403-408 ◽  
Author(s):  
A. G. Ellis ◽  
W. R. Adam ◽  
T. J. Martin
Keyword(s):  
Parathyroid Hormone ◽  
Rat Kidney ◽  
Urine Volume ◽  
Clinical Manifestations ◽  
Fractional Excretion ◽  
Bicarbonate Concentration ◽  
Isolated Perfused Rat Kidney ◽  
Amino Terminal ◽  
Fractional Excretion Of Sodium ◽  
Perfused Rat Kidney

ABSTRACT The isolated perfused rat kidney was used to study the effects of amino-terminal fragments of human parathyroid hormone, hPTH(1–34), bovine parathyroid hormone, bPTH(1–84) and of PTH-related proteins, PTHrP(1–34), PTHrP(1–84), PTHrP(1–108) and PTHrP(1–141) on urinary bicarbonate excretion. PTHrP(1–34) (7 nmol/l), bPTH(1–84) (5·5 nmol/l) and hPTH(1–34) (7 nmol/l) had similar effects in increasing bicarbonate excretion with respect to the control. At lower concentrations (0·7 nmol/l) all PTHrP components, but not hPTH(1–34) or bPTH(1–84) increased bicarbonate excretion significantly. Infusions of PTHrP(1–108) and PTHrP(1–141) at 0·7 nmol/l, while associated with a rise in urinary bicarbonate concentration and excretion during the early stages of perfusion, produced a sharp decline in bicarbonate concentration and excretion in the latter part of perfusion. The different peptides produced no significant differences in glomerular filtration rate, fractional excretion of sodium or urine volume. The absence of substantial differences between the effects of hPTH(1–34) and PTHrP(1–34) are as noted in previous studies. The differences between PTHrP(1–108)/PTHrP(1–141) and PTHrP(1–34) demonstrated here are consistent with (1) the clinical manifestations of acidosis in hyperparathyroidism and alkalosis in humoral hypercalcaemia of malignancy, and (2) an independent action of a component of PTHrP beyond amino acids 1–34. Journal of Endocrinology (1990) 126, 403–408

Effect of epinephrine on renal potassium excretion in the isolated perfused rat kidney

1984 ◽  
Vol 247 (2) ◽  
pp. F331-F338
Author(s):  
L. D. Katz ◽  
J. D'Avella ◽  
R. A. DeFronzo
Keyword(s):  
Rat Kidney ◽  
Fractional Excretion ◽  
Beta Agonist ◽  
Potassium Excretion ◽  
Isolated Perfused Rat Kidney ◽  
Beta Agonists ◽  
Beta Adrenergic Agonists ◽  
Urinary Potassium ◽  
Perfused Rat Kidney ◽  
Renal Potassium Excretion

The effects of beta-agonists (epinephrine, isoproterenol, and ITP) and beta-antagonists (propranolol, metoprolol, and butoxamine) on renal potassium excretion were examined using the isolated perfused rat kidney preparation. Following 30 min of control perfusion, one of the above beta-adrenergic agonists or antagonists was added to the perfusion medium. Following epinephrine, a combined beta 1- and beta 2-agonist, urinary potassium excretion (UKV; 0.55 +/- 0.55 vs. 0.36 +/- 0.04 mueq/min, P less than 0.001) and fractional excretion of potassium (FEK; 24.6 +/- 2.4 vs. 18.2 +/- 2.0%, P less than 0.001) both decreased. When isoproterenol, a nonspecific beta-agonist, was added to the perfusate, UKV (0.49 +/- 0.10 vs. 0.27 +/- 0.04 mueq/min, P less than 0.02) and FEK (29.0 +/- 5.2 vs. 16.3 +/- 2.9%, P less than 0.01) again decreased. ITP, a specific beta 1-agonist also caused a decrease in UKV (0.60 +/- 0.13 vs. 0.39 +/- 0.04 mueq/min, P less than 0.02) and FEK (30.2 +/- 5.1 vs. 17.8 +/- 2.8%, P less than 0.02). In contrast, when propranolol, a nonspecific beta-antagonist, was added to the perfusate, the opposite effects on renal potassium handling were observed. UKV (0.45 +/- 0.05 vs. 0.70 +/- 0.07 mueq/min, P less than 0.001) and FEK (23.0 +/- 2.1 vs. 42.5 +/- 3.1%, P less than 0.001) both increased. Metoprolol (50 ng/ml), a specific beta 1-antagonist, increased UKV (0.56 +/- 0.10 vs. 0.68 +/- 0.15 mueq/min, P less than 0.02) and FEK (31.0 +/- 3.8 vs. 48.0 +/- 7.1%, P less than 0.02). A similar effect was observed when a higher dose of metoprolol (200 ng/ml) was employed.(ABSTRACT TRUNCATED AT 250 WORDS)

Effect of vasoactive intestinal peptide on isolated perfused rat kidney

1985 ◽  
Vol 249 (5) ◽  
pp. E494-E497 ◽  
Author(s):  
R. M. Rosa ◽  
P. Silva ◽  
J. S. Stoff ◽  
F. H. Epstein
Keyword(s):  
Vasoactive Intestinal Peptide ◽  
Rat Kidney ◽  
Urine Volume ◽  
Fractional Excretion ◽  
Rectal Gland ◽  
Renal Nerves ◽  
Isolated Perfused Rat Kidney ◽  
Fractional Excretion Of Sodium ◽  
Perfused Rat Kidney ◽  
Renal Tubular

Vasoactive intestinal peptide, a polypeptide neurotransmitter, stimulates salt secretion by the mammalian intestine and the rectal gland of the dogfish shark. Because of the recent identification of vasoactive intestinal peptide in renal nerves, the present study was undertaken to investigate its effects on the isolated perfused rat kidney. The addition of vasoactive intestinal peptide to the recirculating perfusate produced a significant increase in urine volume, fractional excretion of sodium, chloride, and potassium, as well as osmolar clearance when compared with control kidneys. These changes associated with addition of vasoactive intestinal peptide occurred without any significant changes in perfusion flow, renal vascular resistance, or inulin clearance. These experiments strongly suggest an action of vasoactive intestinal peptide on renal tubular reabsorption.

Inhibition of neutral endopeptidase stimulates renal sodium excretion in patients with chronic renal failure

1993 ◽  
Vol 84 (1) ◽  
pp. 31-39 ◽  
Author(s):  
J. C. Dussaule ◽  
C. Michel ◽  
M. N. Peraldi ◽  
J. M. Lecomte ◽  
C. Gros ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Cyclic Gmp ◽  
Atrial Natriuretic Factor ◽  
Fractional Excretion ◽  
Neutral Endopeptidase ◽  
Factor Level ◽  
Natriuretic Factor ◽  
Fractional Excretion Of Sodium ◽  
Atrial Natriuretic

1. The acute effects of a single oral dose of sinorphan (100 mg), an inhibitor of neutral endopeptidase, on the plasma atrial natriuretic factor level and the fractional excretion of sodium were examined in 12 patients with severe chronic renal failure who were not on maintenance haemodialysis and who ingested a normal sodium diet. The drug was administered against placebo by a double-blind cross-over protocol. 2. Basal plasma atrial natriuretic factor level and fractional excretion of sodium were high (23.2 ± 3.7 pmol/l and 2.64 ± 0.38%, respectively). Sinorphan inhibited plasma neutral endopeptidase activity by 68–75% 30 min after ingestion. This effect persisted for at least 4 h. There were simultaneously increases in plasma atrial natriuretic factor and cyclic GMP levels to 1.9 and 1.4 times the basal values, respectively. Fractional excretion of sodium increased during the second and third hour periods after ingestion of the drug with a peak of 1.9 times the basal value in the second period. Changes in fractional excretion of sodium were significantly correlated with those in plasma atrial natriuretic factor and cyclic GMP levels. Plasma aldosterone level, creatinine clearance and mean blood pressure were unchanged, whereas plasma renin activity increased slightly. An increase in urinary cyclic GMP excretion was observed in parallel with the increase in plasma cyclic GMP level. 3. The results of the present study indicate that (i) high basal values of plasma atrial natriuretic factor level and fractional excretion of sodium, as observed in patients with chronic renal failure, are associated with marked effects of neutral endopeptidase inhibition; (ii) fractional sodium excretion increases after protection of endogenous atrial natriuretic factor from degradation independently of any initial change in extracellular fluid volume or sodium intake, which suggests that this hormone may play a role in the control of sodium excretion in chronic renal failure.

Low correlation between morning spot and 24-hour urine samples for estimating sodium intake in an Iranian population: Isfahan Salt Study

2019 ◽  
Vol 89 (3-4) ◽  
pp. 185-191
Author(s):  
Alireza Khosravi ◽  
Noushin Mohammadifard ◽  
Mojagn Gharipour ◽  
Zahra Abdollahi ◽  
Fatemeh Nouri ◽  
...  
Keyword(s):  
Sodium Excretion ◽  
Salt Intake ◽  
Iranian Population ◽  
Urine Samples ◽  
Potassium Excretion ◽  
Urine Sodium ◽  
Gold Standard Method ◽  
Spot Urine ◽  
Sodium And Potassium ◽  
Tanaka Formula

Abstract. Introduction: Although difficult, the 24-hour urine sodium excretion is still considered as the gold standard method to estimate salt intake. The current study aimed to assess the validity of using spot urine samples in comparison with the standard 24-hour urine collection to estimate sodium and potassium intake in healthy Iranian adults. Methods and subjects: This cross-sectional study was performed on 1099 healthy Iranians aged 18–69 years. Samples of 24-hour and fasting morning spot urine were collected to measure sodium and potassium excretions. Tanaka’s formula was utilized to predict the 24-hour sodium and potassium urinary excretions based on the spot values. Results: The difference between measured and estimated sodium excretion values was 4265 mg/day (95% CI: 4106–4424; P < 0.001) and 2242 mg/day in case of potassium excretion (95% CI: 2140–2344; P < 0.001). There was a weak significant correlation between the 24-hour urine sodium and potassium excretion and the predicted values (intraclass correlations: 0.22 and 0.28, respectively; both P < 0.001). Conclusion: The weak association between the predicted and measured values of sodium and potassium along with the marked overestimation of daily sodium and potassium excretions based on the spot urine and using Tanaka formula indicates that Tanaka formula is not practical for the prediction of sodium and potassium or salt intake in Iranian adults. Using other spot urine sampling times and/or adopting a formula designed based on the characteristics of the Iranian population may increase the validity of spot urine tests.

Neonatal Renal Failure: Usefulness of Diagnostic Indices

PEDIATRICS ◽  
1980 ◽  
Vol 65 (1) ◽  
pp. 57-60 ◽  
Author(s):  
Oommen P. Mathew ◽  
Alan S. Jones ◽  
Elizabeth James ◽  
Harold Bland ◽  
Ted Groshong
Keyword(s):  
Renal Failure ◽  
Fractional Excretion ◽  
Urine Sodium ◽  
Neonatal Renal Failure ◽  
Failure Index ◽  
Diagnostic Indices ◽  
Fractional Excretion Of Sodium

Forty-two oliguric neonates were prospectively studied to evaluate the usefulness and reliability of various diagnostic indices in differentiating renal failure from functional (prerenal) oliguria. Twenty-two infants had functional oliguria, 16 had renal failure, and four infants had probable early renal failure. Statistically significant differences between functional oliguria and renal failure were found with regard to the urine sodium, urine to serum ratios of sodium, urea, and creatinine, renal failure index, and fractional excretion of sodium. However, sharp demarcation of the two groups was possible only when the renal failure index or fractional excretion of sodium was used. Fractional excretion of sodium values of 2.5 or greater seem to differentiate renal failure from functional oliguria in this study.

Sign in / Sign up

Export Citation Format

Share Document